The Washington Post have reported that FDA Commissioner, Scott Gottlieb wants to double the number of staff to intercept disguised opioids coming into America. In an interview to the Associated Press, Gottlieb mentioned a massive growth of shipments from China due to e-commerce, making it difficult for the FDA and US Postal service to intercept shipments.
A recent report from The Guardian released data that opioid overdoses in the US increased by approximately 30% in a 14-month period between 2016 and 2017. Following 142,000 US hospital overdoses between July 2016 and September 2017, the US Centres for Disease Control and Prevention (CDC) described the crisis as a “wake up call to the fast-moving opioid overdose epidemic”.
Commenting on the crisis, acting director of the CDC, Dr Anne Schuchat states that they are “currently seeing the highest overdose death rates ever recorded in the United States.” The opioid crisis is particularly prominent in cities and towns with metropolitan areas seeing a 54% increase. The data revealed that Wisconsin had a 109% increase in overdoses and Delaware a 105% increase.
New psychoactive substances (NPS) such as fentanyl laced with heroin continue to be named as a major problem in the US opioid crisis with officials emphasizing the dangers of the toxic substances. The White House has since announced their decision to provided new funding to treat those affected by the epidemic.
As part of our unrivalled toxicology test menu, Randox Toxicology's NPS II panel detects designer fentanyl and opioids. Our level of expertise in toxicology research and development allows us to adapt quickly to the ever-changing market influences and develop assays for current and novel drug trends. In addition to this, our DoA ULTRA panel detects 20 targeted drugs and provides the largest cross-reactivity profile of over 240 analytes.
If you would like to find out more information about our NPS II and DoA ULTRA panels, email us at info@randoxtoxicology or visit us at www.randoxtoxicology.com